In-Depth Market Analysis On Melanoma Pipeline Review, H1 2016

Melanoma Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. 

To view the table of contents and know more details please visit Melanoma Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Melanoma
- The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Melanoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Melanoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

4SC AG AB Science SA AbbVie Inc. ACF Pharmaceuticals, LLC Adamis Pharmaceuticals Corporation Adaptimmune Therapeutics Plc Adicet Bio, Inc. Aduro BioTech, Inc. Advaxis, Inc. Aeterna Zentaris Inc. Affichem SA Agalimmune Ltd Agenus, Inc. Agilvax, Inc. AGV Discovery, SAS AIMM Therapeutics B.V. Alethia Biotherapeutics Inc. Altor BioScience Corporation Amgen Inc. Anavex Life Sciences Corp. Angimmune LLC Antibe Therapeutics, Inc. Antigen Express, Inc. APEIRON Biologics AG Apexigen, Inc. Aphios Corporation APO-T B.V. Apogenix GmbH Aposense Ltd. Aptose Biosciences Inc. Arisaph Pharmaceuticals, Inc. Array BioPharma Inc. Asana BioSciences, LLC Astex Pharmaceuticals, Inc. AstraZeneca Plc Aurigene Discovery Technologies Limited Azaya Therapeutics, Inc. Basilea Pharmaceutica AG Batu Biologics, Inc. Bayer AG BeiGene, Ltd. Beijing Kawin Technology Share-Holding Co., Ltd. etc,.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###